The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
Kyowa Kirin delivered double-digit growth in group revenue on the back of strong overseas performances in the year through December 2024, but it suffered a big bottom-line drop due to swelling R&D outlays. According to its earnings released on February…
To read the full story
Related Article
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
- Kyowa Kirin Sees Need for Shift of Japan Business: CEO
February 10, 2025
- Kyowa Kirin’s H1 Sales up 16.9% on North American Biz, Strategic Brands
August 5, 2024
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned
May 11, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
- Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
August 5, 2022
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…